	Quest	Maternal Serum	BILLTO:	PRINT PATIENT NAME (LAST, FIRS	T, MIDDLE)				
0	Diagnostics [®]	Screening New York	☐ My Account	REGISTRATION # (IF APPLICABLE)	DATE M	M D D YEAR	SEX		
1111		_	☐ Insurance Provided	REGISTRATION # (IF AFFLICABLE)	OF OF	INI B B TEAR	IIII		
			☐ Lab Card/Select ☐ Patient	LAB REFERENCE #	BIRTH	CELL PHONE			
•			ratient			()			
_			Are Performed At	PATIENT ID # / MI	RN	PATIENT PHONE			
0		An Additiona	-	DATIFALT FAMALL A	DDDFGG	()			
i	ACCOUNT #:	PSC Appoints Number Info	ment Website And Tel mation Listed On The	ephone PATIENT EMAIL A Back.	DDKE55				
	NAME:		Should Be Labeled W	lith At Loost	IRED/RESPONSIRI E PARTY (I AS	ST, FIRST, MIDDLE) - IF OTHER THAN PATIE	ENT C		
O	ADDRESS: CITY, STATE, ZIP	Two Patient	dentifiers At Time Of	Collection.	DIED/TIEST ONSIDEE FAITT (EAG	SI, TITIOT, WILDDELF - IF OTHER THAN FAIL			
ar)	TELEPHONE #:		osis Codes are M		DDRESS (OR INSURED/RES	PONSIBLE PARTY) APT. # KEY	# F S		
			applicable fields	below.		,			
ece	DATE COLLECTED TIME	=l	☐ Fasting ☐ Non Fasting	CITY	Is	TATE ZIP			
	NPI/UPIN ORDERING/SUPERVISING PH	$\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ $					ap Sis		
			ATED)	RELATIONSHIPTO INSURED:	☐ SELF ☐ SP	OUSE DEPENDENT			
ııı. A			UR/	PRIMARY INSURANCE CO. NAME			Suig		
			NSI	MEMBER / INSURED ID NO. #	GRO	JP #			
A			=						
e signed A			[∢]	NSURANCE ADDRESS	•				
O <u></u>			Z Z	CITY		STATE ZIP			
S.			<u>~</u>				be		
				ABN required f	or tests with th	nese symbols			
Provide			Me	edicare @= May not be covered	for the reported diagnosis	Provide			
₫	ADDIT'L PHYS.: Dr	NPI/UPIN L L L L		mited F = Has prescribed freq	uency rules for coverage. rformed with research/exp	signed erimental kit ARN wh			
0	NON-PHYSICIAN NAME PROVIDER:	I.D.#		Tests B = Has both diagnosis	and frequency-related cov	erage limitations. necessa	ary 🔼		
	☐ Fax Results to: ()	·	VI	sit QuestDiagnostics.co	es (enter all that		es		
	Send Client # OR NAME:			10000					
\bigcirc	Duplicate ADDRESS: Report to: CITY:	STATEZIP	Many those	payers (including Medicare and Medi tests which are medically necessary t	caid) have medical necessit for the diagnosis and treatm	y requirements. You should only ordent of the patient.	der		
FOLD HERE	721.	1st TRIMESTER SC		ester Screening does not detec		SST T	FALL		
	& 16969	reen hyperGly-hCG (PAPP-A, h-hCG) (9.0-1	-		en, hCG (PAPP-A, hCC	G) (10.0-13.9 wks gestation)	\ 		
essa)	2 1607/ Sequential Inte	grated Screen Part 1 (PAPP-A, hCC	INTEGRATED/SEQUEN	TIAL SCREENING 1976	Part 1 (DADD_A) # A	NT required)	rovide		
ece C	gg (10.0-13.9 week	(s gestation)		(9.0-13.9 weeks ges					
_ (= 169/5 ☐ Sequential Inte	16975 Sequential Integrated Screen <i>Part 2</i> (AFP, hCG, uE3, DIA) (14.0-22.9 weeks gestation)			16977 Integrated Screen Part 2 (AFP, hCG, uE3, DIA) (14.0-22.9 weeks gestation)				
hen	Specimen # f	From Part 1		Specimen # from Part 1					
	& 16464 ☐ Stepwise Sequ (10.0-13.9 week	ential Screen Part 1 (PAPP-A, hCG)	# ♦ & 16	& 16973 ☐ Serum Integrated Screen <i>Part 1</i> (PAPP-A) # (NT not required) (9.0-13.9 weeks gestation)					
N.	16466 Stepwise Segu	ential Screen Part 2 (AFP, hCG, uE	3, DIA) 16	966 Serum Integrated S		CG. uE3. DIA)	ABN w		
<u>A</u>	(14.0-22.9 week	ks gestation) From Part 1		(14.0-22.9 weeks ge	station)		\		
Signed ABN wh	Opecimen # 1		2nd TRIMESTER	Specimen # from SCREENING #	rait i	SST 1			
<u>iĝ</u>	@ 92788	m AFP (MSAFP)		333	hCG, uE3, DIA)		3		
	(15.0-22.9 wee	eks gestation) ibe detects (oNTDs) only				2CV4E 0 22 0l	nece		
rovide	ul soitso		RED FOR <u>all tests</u> ~ <u>ca</u>	970 Penta Screen (AFP)	, ncg, ues, dia, h-hi IY QUESTI <u>ons</u>	וטט-22.9 wks gestatio), וטכ	on) S		
§	Date of Birth:/_			ternal Weight: LBS			sary		
\cap :	# THIS	INFORMATION IS REQUIRED FOR PART				·	Tube		
Ssary	Estimated Date of Delivery	(EDD):/ determin	ned by: 🗌 Ultrasou	nd Last Menstrual Perio	d (LMP) 🗌 Physical	Exam	3		
≅ ~ 	# I Number of Fetuses: On	African American ☐ Asian ☐ Ca	iucasian 🗀 Hispan v manv fetuses?	ic Utner:					
Yes No									
		lin-dependent diabetic prior to pregn pecimen for this pregnancy (Repeat t		eroon positive result for Dow	n syndromo or Trison	ov 18 is NOT recommende	'4' <mark>d</mark>		
	☐ History of neural	tube defect					¹⁴⁾ 2		
∠ ≥		ncv with Down Syndrome		l:			Provide signed ABN		
B	Patient currently	smokes cigarettes	anie or Lyg netrieva				¦ž		
Signed ABN	Other Relevant C	linical Information: JIRED FOR 1st TRIMESTER SCREENING A	NID DADT 1 INTEGRAT	ED/SEQUENTIAL SOREMING		1	<u> </u> \ O		
je P	Ultrasound date /	JIRED FUR 1st TRIMESTER SCREENING A / Ultrasonographer's name		ED/SEQUENTIAL SCREENING.			ien :		
Sig	Nuchal Translucency Mea	asurement Credentialing Agency	(required, check of	one box)	+		ie		
しょう		Location ID #		Reading Physician ID#	1 1		I ¦ŏ ∪		
Ge G	FMF Ultrasonographer's ID#	Cocation 10 #		ID#			<u>P</u>		
		Other (List)		ID#			when necessary		

0	INFORMED CONSENT MATERNAL SERUM SCREENING	0				
0	Integrated/Sequential Screening (Integrated Screen, Sequential Integrated Screen and Serum Integrated Screen) is offered to screen for certain chromosome disorders, such as Down syndrome and trisomy 18. Integrated Screen may lead to the detection of 94-96% of fetuses with Down syndrome and 90% of fetuses with trisomy 18. Sequential Integrated Screen may lead to the detection of 95% of fetuses with					
0	Down syndrome and 90% of fetuses with trisomy 18. Serum Integrated Screen may lead to the detection of 85-88% of fetuses with Down syndrome and 90% of fetuses with trisomy 18. Integrated/Sequential Screening are also offered to screen for open neural tube defects and may lead to the detection of 95% of fetuses with anencephaly and 65-80% of fetuses with open spina bifida. Thus, Integrated/Sequential Screening will not lead to the detection of all fetuses with open neural tube defects, Down syndrome or trisomy 18.	0				
0	First Trimester Maternal Serum Screening (1st Trimester Screen with hyperGly-hCG and 1st Trimester Screen with hCG) is offered to screen for certain chromosome disorders, such as Down syndrome and trisomy 18. 1st Trimester Screen with hyperGly-hCG may lead to the detection of 83% of fetuses with Down syndrome and 75% of fetuses with trisomy 18. 1st Trimester Screen with hCG may lead to the detection of 82-87% of fetuses with Down syndrome and 75% of fetuses with trisomy 18. Thus, First Trimester Maternal Serum Screening	0				
0	will not lead to the detection of all fetuses with Down syndrome or trisomy 18. Also, First Trimester Maternal Serum Screening will not lead to the detection of open neural tube defects.	0				
O 	Second Trimester Maternal Serum Screening (MSAFP, Triple Screen, Quad Screen and Penta Screen) is offered to screen for open neural tube defects and may lead to the detection of 95% of fetuses with anencephaly and 65-80% of fetuses with open spina bifida. Triple Screen, Quad Screen and Penta Screen are offered to screen for certain chromosome disorders, such as Down syndrome and trisomy 18. Triple Screen may lead to the detection of 69% of fetuses with Down syndrome and 73% of fetuses with trisomy 18. Quad Screen may lead to the detection of 81% of fetuses with Down syndrome and 73% of fetuses with trisomy 18. Penta Screen may lead to the detection of 83% of fetuses with Down syndrome and 73% of fetuses with trisomy 18. Thus, Second Trimester Maternal Serum Screening will not lead to the detection of all fetuses with open neural tube defects, Down syndrome or trisomy 18. Also, MSAFP will not lead to the detection of Down syndrome or trisomy 18.	0				
0	2. Neural tube defects (such as spina bifida and anencephaly) occur when the spine and brain do not develop completely. Down syndrome and trisomy 18 result from the presence of an extra chromosome (numbers 21 and 18, respectively) and cause both mental and physical abnormalities.	0				
0	Some open neural tube defects and those covered with skin may not be detected. Most other birth defects and mental retardation are NOT detectable by Maternal Serum Screening.					
0	4. Screen positive results mean further testing may be necessary to determine if the fetus has a neural tube defect, Down syndrome or trisomy 18. Such testing may include a repeat Maternal Serum Screen test, ultrasound, removal and testing of a small amount of chorionic villi (CVS), or removal and testing of a small amount of amniotic fluid (amniocentesis).					
	5. Screen positive results may occur for reasons such as: miscalculation of due date, twin pregnancy, vaginal bleeding, or the presence of other rare birth defects. Sometimes the results are screen positive for no apparent reason.	 - -				
O 	6. At the request of your physician, screen positive results will be given to a diagnostic center for follow-up. I certify that I have read the above consent and understand its content, including the BENEFITS and LIMITATIONS of Maternal Serum Screening and request that it be performed. I have discussed the test with my physician.					
0	Patient Signature (required for New York residents only) Date Physician Signature (required for New York residents only) Date	0				
0	 	0				
0		0				
0		0				
0		0				
0		0				
0	 	0				
0		0				
0	Patients: Minimize your wait time by scheduling an appointment at a convenient Patient Service Center. To find a location and make an appointment visit us at QuestDiagnostics.com/appointment or call 888-277-8772 or simply download our mobile app. at QuestDiagnostics.com/mobile	0				

Co. Ourock	Mataural Course	BILLTO:	PRINT PATIEN	IT NAME (LAST, FIRST, MID	DLE)		
Quest Diagnostics®	Maternal Serum Screening New York	☐ My Account					
Diagnostics	Screening New York	☐ Insurance Provided	REGISTRATIO	N # (IF APPLICABLE)	DATE OF	M M D D	YEAR SEX
		☐ Lab Card/Select			BIRTH		
		☐ Patient	LAB REFEREN	ICE #		CELL PHONE	
				PATIENT ID # / MRN		PATIENT PHON	NF
		Are Performed At		AILUI ID # / MINI		()	
	An Additiona	•		PATIENT EMAIL ADDRE	:ee	()	
ACCOUNT #:	PSC Appoints	ment Website And Tel rmation Listed On The	lephone Back	PATIENT EWAIL ADDRE	.55		
NAME:		Should Be Labeled V		DDIAIT ALABAS OF IAIOLIDED (DE	FORONIOIDI E DARTIVI	A OT FIRST A AIRRIES	OTLIED THAN DATIENT
ADDRESS:	Two Patient	Identifiers At Time Of	Collection.	PRINT NAME OF INSURED/RE	ESPONZIBLE PARTY (L	AST, FIRST, MIDDLE) - IF (UTHER THAN PATIENT
CITY, STATE, ZIP	□ ICD Diagn	osis Codes are M	landatory.				1 1 1 1
FELEPHONE #:		applicable fields		PATIENT STREET ADDRES	S (OR INSURED/RE	SPONSIBLE PARTY)	APT. # KEY #
DATE COLLECTED TIME	AM TOTAL VOL/HRS.	☐ Fasting					
:		_ Non asting	CITY	_		STATE ZIP	
IPI/UPIN ORDERING/SUPERVISING F	PHYSICIAN AND/OR PAYERS (MUST BE INDIC		DEL ATIONICI	HIPTO INSURED:	SELF S	POUSE DI	EPENDENT
		RANG		RANCE CO. NAME	SELF US	POUSE DI	EPENDENT
		Ę l					
		SN	MEMBER / INSU	JRED ID NO. #	GRO	OUP#	
		<u>.</u>					
		< <	INSURANCE AD	DRESS			1
		PRIM	CITY			STATE ZIP	
		E				JOIAIL ZII	
				l ve avrive d few t		h	ala
		NA.		I required for to May not be covered for the			Provide
ADDIT'L PHYS.: Dr	NPI/UPINL L L L	<u>, , , , , , , , , , , , , , , , , , , </u>	.imited F =	Has prescribed frequency	rules for coverage.		signed
ION-PHYSICIAN NAME	I.D.#		overage & = Tests B =	A test or service performe Has both diagnosis and fre	d with research/ex equency-related co	perimental kit. verage limitations.	ABN when necessary
PROVIDER: Fax Results to: ()		Vi	isit QuestDi	iagnostics.com/M			e guidelines
end Client # OR NAME:				ICD Codes (e	enter all tha	t apply)	
uplicate ADDRESS:		Many	payers (including	g Medicare and Medicaid) h medically necessary for the	lave medical necess	ity requirements. You	u should only order
eport to: CITY:	STATE ZIP					nent of the patient.	
2 16969 □ 1st Trimester S	reen hyperGly-hCG (PAPP-A, h-hCG) (9.0-1			ng does not detect oNT		C) /10 0 13 9 w/	SST Tube
Revision 120 CO CO CO		INTEGRATED/SEQUEN			od (i Ai i A, iid	7G) (10.0 10.0 W	ks gestation,
& 16974 ☐ Sequential Int (10.0-13.9 wee	egrated Screen Part 1 (PAPP-A, hCG		6976 □Inte	grated Screen <i>Part</i> 1 -13.9 weeks gestation		(NT required)	I I
16975 Sequential Int	egrated Screen Part 2 (AFP, hCG, ul	E3, DIA) 16	6977	grated Screen Part	2 (AFP, hCG, ul	E3, DIA)	
(14.0-22.9 wed Specimen #	eks gestation) from Part 1	į		0-22.9 weeks gestation Ecimen # from Part			equired)
₹ & 16464 ☐ Stepwise Seq	uential Screen Part 1 (PAPP-A, hCG)			um Integrated Screer	n Part 1 (PAPP		equired)
(10.0-13.9 wee				-13.9 weeks gestation			I
§ 16466 □ Stepwise Seq (14.0-22.9 wee	uential Screen Part 2 (AFP, hCG, uE	3, DIA) 16	6966 □Seru (14.0	um Integrated Screer 0-22.9 weeks gestatio	n Part 2 (AFP,	hCG, uE3, DIA)	I I
Specimen #	from Part 1		Spe	ecimen # from Part			
TSET		2nd TRIMESTER					equired) SST Tube
@ 92788	um AFF (IVISAFF) eks gestation)	16	6333 □ Qua (14.)	ad Screen (AFP, hCG 0-22.9 weeks gestati	i, uE3, DIA) ion)		! ! !
	ube detects (oNTDs) only			ita Screen (AFP, hCC		nCG)(15.0-22.9	1
nostics	THIS INFORMATION IS REQUI	IRED FOR ALL TESTS ~ CA	ALL 866-GENEIN	IFO IF YOU HAVE ANY QUE	STIONS		The gootation,
Date of Birth:/			aternal Weig				1
S .	S INFORMATION IS REQUIRED FOR PART						•
	y (EDD):/ determin						i
Mother's Ethnic Origin:	☐ African American ☐ Asian ☐ Ca	aucasian 🗀 Hispan	nic 🗆 Other	:			¦
Yes No	ne 🗌 Two 🗌 More than 2 Hov						i
🚆 🔲 🔲 Patient is an ins	ulin-dependent diabetic prior to pregn						ecommended)
This is a repeat History of neural History	specimen for this pregnancy (Repeat t						ecommended)
Previous pregna	ncy with Down Syndrome						
Pregnancy is from Patient currently		time of Egg Retrieva	al:				¦
Patient currently					_		!
other Relevant	Clinical Information:						, 1
	Clinical Information: LUIRED FOR 1st TRIMESTER SCREENING F	AND PART 1 INTEGRAT	TED/SEQUEN <u>ti</u>	IAL SCREENING.	+		+ !
◆ THIS INFORMATION IS RECU	UIRED FOR 1st TRIMESTER SCREENING A						+ ;
◆ THIS INFORMATION IS RECUltrasound date/ Nuchal Translucency Moderation National Translucency National Transluc	UIRED FOR 1st TRIMESTER SCREENING A Ultrasonographer's name easurement Credentialing Agency Location ID #	(required, check o	one box)	ian ID#	-		+ ;
◆ THIS INFORMATION IS RECUltrasound date/ Nuchal Translucency Moderation National Translucency National Transluc	UIRED FOR 1st TRIMESTER SCREENING A Ultrasonographer's name easurement Credentialing Agency Location ID #	(required, check o	one box)	ian ID#	-		+ ;
◆ THIS INFORMATION IS RECOUNT OF THIS INFORMATION IS RECOUNT	UIRED FOR 1st TRIMESTER SCREENING A _/ UItrasonographer's name easurement Credentialing AgencyLocation ID # Other (List)	(required, check o	one box) Reading Physic	ian ID#	-		+ !
◆ THIS INFORMATION IS RECOUNTS INFORMATION INFORMATION IS RECOUNTS INFORMATION INFORMATIO	UIRED FOR 1st TRIMESTER SCREENING A Ultrasonographer's name easurement Credentialing Agency Location ID #	r (required, check of	one box) Reading PhysicID#	ian ID#osent	+		+

0	INFORMED CONSENT MATERNAL SERUM SCREENING	0				
0	Integrated/Sequential Screening (Integrated Screen, Sequential Integrated Screen and Serum Integrated Screen) is offered to screen for certain chromosome disorders, such as Down syndrome and trisomy 18. Integrated Screen may lead to the detection of 94-96% of fetuses with Down syndrome and 90% of fetuses with trisomy 18. Sequential Integrated Screen may lead to the detection of 95% of fetuses with					
0	Down syndrome and 90% of fetuses with trisomy 18. Serum Integrated Screen may lead to the detection of 85-88% of fetuses with Down syndrome and 90% of fetuses with trisomy 18. Integrated/Sequential Screening are also offered to screen for open neural tube defects and may lead to the detection of 95% of fetuses with anencephaly and 65-80% of fetuses with open spina bifida. Thus, Integrated/Sequential Screening will not lead to the detection of all fetuses with open neural tube defects, Down syndrome or trisomy 18.	0				
0	First Trimester Maternal Serum Screening (1st Trimester Screen with hyperGly-hCG and 1st Trimester Screen with hCG) is offered to screen for certain chromosome disorders, such as Down syndrome and trisomy 18. 1st Trimester Screen with hyperGly-hCG may lead to the detection of 83% of fetuses with Down syndrome and 75% of fetuses with trisomy 18. 1st Trimester Screen with hCG may lead to the detection of 82-87% of fetuses with Down syndrome and 75% of fetuses with trisomy 18. Thus, First Trimester Maternal Serum Screening	0				
0	will not lead to the detection of all fetuses with Down syndrome or trisomy 18. Also, First Trimester Maternal Serum Screening will not lead to the detection of open neural tube defects.	0				
O 	Second Trimester Maternal Serum Screening (MSAFP, Triple Screen, Quad Screen and Penta Screen) is offered to screen for open neural tube defects and may lead to the detection of 95% of fetuses with anencephaly and 65-80% of fetuses with open spina bifida. Triple Screen, Quad Screen and Penta Screen are offered to screen for certain chromosome disorders, such as Down syndrome and trisomy 18. Triple Screen may lead to the detection of 69% of fetuses with Down syndrome and 73% of fetuses with trisomy 18. Quad Screen may lead to the detection of 81% of fetuses with Down syndrome and 73% of fetuses with trisomy 18. Penta Screen may lead to the detection of 83% of fetuses with Down syndrome and 73% of fetuses with trisomy 18. Thus, Second Trimester Maternal Serum Screening will not lead to the detection of all fetuses with open neural tube defects, Down syndrome or trisomy 18. Also, MSAFP will not lead to the detection of Down syndrome or trisomy 18.	0				
0	2. Neural tube defects (such as spina bifida and anencephaly) occur when the spine and brain do not develop completely. Down syndrome and trisomy 18 result from the presence of an extra chromosome (numbers 21 and 18, respectively) and cause both mental and physical abnormalities.	0				
0	Some open neural tube defects and those covered with skin may not be detected. Most other birth defects and mental retardation are NOT detectable by Maternal Serum Screening.					
0	4. Screen positive results mean further testing may be necessary to determine if the fetus has a neural tube defect, Down syndrome or trisomy 18. Such testing may include a repeat Maternal Serum Screen test, ultrasound, removal and testing of a small amount of chorionic villi (CVS), or removal and testing of a small amount of amniotic fluid (amniocentesis).					
	5. Screen positive results may occur for reasons such as: miscalculation of due date, twin pregnancy, vaginal bleeding, or the presence of other rare birth defects. Sometimes the results are screen positive for no apparent reason.	 - -				
O 	6. At the request of your physician, screen positive results will be given to a diagnostic center for follow-up. I certify that I have read the above consent and understand its content, including the BENEFITS and LIMITATIONS of Maternal Serum Screening and request that it be performed. I have discussed the test with my physician.					
0	Patient Signature (required for New York residents only) Date Physician Signature (required for New York residents only) Date	0				
0	 	0				
0		0				
0		0				
0		0				
0		0				
0	 	0				
0		0				
0	Patients: Minimize your wait time by scheduling an appointment at a convenient Patient Service Center. To find a location and make an appointment visit us at QuestDiagnostics.com/appointment or call 888-277-8772 or simply download our mobile app. at QuestDiagnostics.com/mobile	0				